Trial Profile
An Open-label Phase I Study to Evaluate the Safety, Tolerability and Biodegradation Period of PolyActiva PA5108 Ocular Implant When Administered Intracamerally to the Anterior Chamber of the Eye
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2020
Price :
$35
*
At a glance
- Drugs Latanoprost (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions
- Sponsors PolyActiva
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2020 Planned End Date changed from 31 Jul 2020 to 1 Sep 2020.
- 04 Mar 2020 Planned primary completion date changed from 1 May 2019 to 1 May 2020.